These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

388 related items for PubMed ID: 30423357

  • 1. Mechanisms underlying acquired platinum resistance in high grade serous ovarian cancer - a mini review.
    Binju M, Padilla MA, Singomat T, Kaur P, Suryo Rahmanto Y, Cohen PA, Yu Y.
    Biochim Biophys Acta Gen Subj; 2019 Feb; 1863(2):371-378. PubMed ID: 30423357
    [Abstract] [Full Text] [Related]

  • 2. Studying platinum sensitivity and resistance in high-grade serous ovarian cancer: Different models for different questions.
    Alkema NG, Wisman GB, van der Zee AG, van Vugt MA, de Jong S.
    Drug Resist Updat; 2016 Jan; 24():55-69. PubMed ID: 26830315
    [Abstract] [Full Text] [Related]

  • 3. Biomarkers of platinum resistance in ovarian cancer: what can we use to improve treatment.
    van Zyl B, Tang D, Bowden NA.
    Endocr Relat Cancer; 2018 May; 25(5):R303-R318. PubMed ID: 29487129
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. The Application of Biomaterials in the Treatment of Platinum-Resistant Ovarian Cancer.
    Levy A, Leynes C, Baig M, Chew SA.
    ChemMedChem; 2019 Nov 06; 14(21):1810-1827. PubMed ID: 31456347
    [Abstract] [Full Text] [Related]

  • 7. Low drug resistance to both platinum and taxane chemotherapy on an in vitro drug resistance assay predicts improved survival in patients with advanced epithelial ovarian, fallopian and peritoneal cancer.
    Matsuo K, Bond VK, Eno ML, Im DD, Rosenshein NB.
    Int J Cancer; 2009 Dec 01; 125(11):2721-7. PubMed ID: 19530239
    [Abstract] [Full Text] [Related]

  • 8. Flavonoids Restore Platinum Drug Sensitivity to Ovarian Carcinoma Cells in a Phospho-ERK1/2-Dependent Fashion.
    Koren Carmi Y, Mahmoud H, Khamaisi H, Adawi R, Gopas J, Mahajna J.
    Int J Mol Sci; 2020 Sep 07; 21(18):. PubMed ID: 32906729
    [Abstract] [Full Text] [Related]

  • 9. Response rates to second-line platinum-based therapy in ovarian cancer patients challenge the clinical definition of platinum resistance.
    Lindemann K, Gao B, Mapagu C, Fereday S, Emmanuel C, Alsop K, Traficante N, Australian Ovarian Cancer Study Group, Harnett PR, Bowtell DDL, deFazio A.
    Gynecol Oncol; 2018 Aug 07; 150(2):239-246. PubMed ID: 29807697
    [Abstract] [Full Text] [Related]

  • 10. Medical therapy of advanced malignant epithelial tumours of the ovary.
    Colombo N, Parma G, Bocciolone L, Franchi D, Sideri M, Maggioni A.
    Forum (Genova); 2000 Aug 07; 10(4):323-32. PubMed ID: 11535983
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Improved survival trends in platinum-resistant patients with advanced ovarian, fallopian or peritoneal cancer treated with first-line paclitaxel/platinum chemotherapy: the impact of novel agents.
    Bamias A, Bamia C, Zagouri F, Kostouros E, Kakoyianni K, Rodolakis A, Vlahos G, Haidopoulos D, Thomakos N, Antsaklis A, Dimopoulos MA.
    Oncology; 2013 Aug 07; 84(3):158-65. PubMed ID: 23296063
    [Abstract] [Full Text] [Related]

  • 14. Genomic and Epigenomic Signatures in Ovarian Cancer Associated with Resensitization to Platinum Drugs.
    Fang F, Cardenas H, Huang H, Jiang G, Perkins SM, Zhang C, Keer HN, Liu Y, Nephew KP, Matei D.
    Cancer Res; 2018 Feb 01; 78(3):631-644. PubMed ID: 29229600
    [Abstract] [Full Text] [Related]

  • 15. New markers for human ovarian cancer that link platinum resistance to the cancer stem cell phenotype and define new therapeutic combinations and diagnostic tools.
    Muñoz-Galván S, Felipe-Abrio B, García-Carrasco M, Domínguez-Piñol J, Suarez-Martinez E, Verdugo-Sivianes EM, Espinosa-Sánchez A, Navas LE, Otero-Albiol D, Marin JJ, Jiménez-García MP, García-Heredia JM, Quiroga AG, Estevez-Garcia P, Carnero A.
    J Exp Clin Cancer Res; 2019 Jun 03; 38(1):234. PubMed ID: 31159852
    [Abstract] [Full Text] [Related]

  • 16. A chemoresponse assay for prediction of platinum resistance in primary ovarian cancer.
    Krivak TC, Lele S, Richard S, Secord AA, Leath CA, Brower SL, Tian C, Moore RG.
    Am J Obstet Gynecol; 2014 Jul 03; 211(1):68.e1-8. PubMed ID: 24530815
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients.
    Holloway RW, Mehta RS, Finkler NJ, Li KT, McLaren CE, Parker RJ, Fruehauf JP.
    Gynecol Oncol; 2002 Oct 03; 87(1):8-16. PubMed ID: 12468336
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.